JM
Therapeutic Areas
BeyondSpring Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Plinabulin + G-CSF | Prevention of Chemotherapy-Induced Neutropenia (CIN) | Phase 3 |
| Plinabulin + Docetaxel | Non-Small Cell Lung Cancer (NSCLC) - 2nd/3rd Line | Phase 3 |
| Plinabulin + Radiotherapy & Immunotherapy | Various Solid Tumors (post-ICI failure) | Investigator-Initiated Trials |
Leadership Team at BeyondSpring
LH
Lan Huang, Ph.D.
Co-founder, Chairman & Chief Executive Officer
JL
June Lu, Ph.D.
Chief Scientific Officer
HL
Helen Li, M.D.
Vice President, Clinical Science
HZ
Hao Zhang
Senior Director of Chemical Manufacturing Control (CMC)
JJ
Joy Jia
Vice President, Finance
SX
Sihai Xu, M.B.A.
Director
J(
Jiangwen (Jen) Majeti, Ph.D., M.B.A.
Director